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ABSTRACT 
Anti-colitis effect of antidepressants has been demonstrated recently. Doxepin, a tricyclic antidepressant drug 
(TCA), with potent H1, H2, alpha1 adrenergic and muscarinic receptor blocking effects could be a good candidate 
for investigation for its anti-colitis activity. Moreover high prevalence of depression in patients who suffer from 
IBD (inflammatory bowel disease), defends this idea that adjuvant therapy with an antidepressant drug which has 
anti-inflammatory effect, may exert favorable effects in the control of the disease. In this study colitis was induced 
by acetic acid instillation into rat’s colon. Doxepin was injected by intraperitoneal (10, 20, 40 mg/kg, twice daily, 
i.p.) or intracerebroventricular (50 and 100 microgram/rat, i.c.v.) routes to separate the mechanisms are absolutely 
exerted centrally or mediated both centrally and peripherally prior to induction of colitis. Dexamethasone 
(2 mg/kg/day, i.p.) was used as reference drug. All the treatments continued for three successive days. The effec-
tiveness of drug was evaluated by determination of cytokines (TNFα, IL6 and IL1β) and myeloperoxidase (MPO) 
activity as well as macroscopic scores and histopathological parameters. Doxepin after i.p. administration was 
effective to reduce colitis severity through reduction in the macroscopic and microscopic colonic parameters, MPO 
activity and cytokines levels. Intracerebroventricular administration of the drug in contrast, did not show any sig-
nificant protective effect suggesting no important central mechanisms for anti-colitis activity of doxepin. Doxepin 
as an ancient antidepressive drug has anti-colitis and anti-inflammatory properties which are mainly exerted pe-
ripherally so it could be introduced as a good candidate for depressed people who suffered from IBD disorders. 
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INTRODUCTION 
Inflammatory bowel disease (IBD) is a 
bowel disorder that distinguished by inci-
dences of exacerbations and relieves periodi-
cally, and it includes some kinds of disorders 
such as ulcerative colitis (UC) and Crohn's 
disease (CD) (Bernstein et al., 2009). Clinical 
manifestations of these disorders are edema 
and ulceration of the colon so that cause some 
symptoms in patient such as abdominal pain, 
bloody or mucosal diarrhea, fever, reduced 
body weight and weakness (Thoreson and 
Cullen, 2007). Prolonged IBD can cause 
many psychological problems in patient 
(Sajadinejad et al., 2012). It has shown that 
psychiatric disorders are more common in 
IBD patients compared to other people 
(Kurina et al., 2001) and these disorders have 
more severe symptoms while the disease is 
severe (Graff et al., 2009). There are high 
prevalence of depression (30 %) over remis-
sion period and anxiety (80 %) and depres-
sion (55 %) over relapse period (Mikocka-
Walus et al., 2012a). In addition the risk fac-
tors for relapse are some psychiatric disorders 
like depression (Häuser et al., 2011). The 
studies have shown antidepressant medica-
tions improve some symptoms of IBD such as 
urgency of defecation and pain (Mikocka-
Walus et al., 2012b; Mikocka-Walus et al., 
2006). 
Antidepressant medications have several 
pharmacological properties whereas their 
mechanisms of actions are not completely ob-
vious (Pollack and Doyle, 2003; Rahimi et al., 
2009; Sawynok et al., 2001). Some recent in-
vestigations suggest that antidepressants pro-
duce both in vitro and in vivo anti-inflamma-
tory activities (Hajhashemi et al., 2015; 
Kostadinov et al., 2014; Sadeghi et al., 2013; 
Sutcigil et al., 2007; Sacre et al., 2010). 
Our previous studies also demonstrated 
the anti-inflammatory activities of amitripty-
line, fluvoxamine, maprotiline and venlafax-
ine (Hajhashemi et al., 2010, 2015; Sadeghi et 
al., 2011, 2013) and anti-colitis effects of 
maprotiline and fluvoxamine (Minaiyan et al., 
2014, 2015). 
Doxepin, a TCA with a tertiary amine, in-
hibits the reuptake of norepinephrine (NE) 
and serotonin (5HT) and exerts a very weak 
inhibition of dopamine (DA) reuptake. Its ac-
tive metabolite, desmethyldoxepin (nordox-
epin), has also some antidepressant effects. 
Doxepin binds strongly to histamine H1 and 
H2 receptors (Shibuya et al., 2012; Ahles et 
al., 1984; Shimamura et al., 2011). It also has 
some antagonistic effects on 5-HT, alpha1 ad-
renergic and muscarinic cholinergic receptors 
(Singh and Becker, 2007). 
Doxepin is approved for treatment of ma-
jor depression (MDD) and insomnia 
(Wichniak et al., 2012), as a part of the treat-
ment of chronic urticaria (Negro-Alvarez et 
al., 1996) and in pain management (Godfrey, 
1996; Sansone and Sansone, 2008). 
The roles of some nervous systems and 
mediators in the pathogenesis of colitis such 
as sympathetic nervous system (SNS) (Straub 
et al., 2006), histamine (Fogel et al., 2005; 
Xie and He, 2005), serotonin (Ghia et al., 
2009; Shajib and Khan, 2015) and dopamine 
(Tolstanova et al., 2010), make doxepin as a 
good candidate for therapy of inflammatory 
conditions such as IBD. 
The present study was aimed to evaluate 
the effect of doxepin on experimental colitis 
in rats. For more clear detection of peripheral 
and/or central roles of doxepin effect in this 
experiment, we applied the drug by either i.p. 
or i.c.v. injections. 
 
MATERIALS AND METHODS 
Animals 
Male Wistar rats weighing about 200–
250 g were purchased of the animal house of 
the School of Pharmacy, Isfahan University 
of Medical Sciences, Isfahan, Iran. The rats 
were housed in groups of 6 in temperature and 
humidity controlled rooms (20–23 °C, 50–
60 %) with a 12 h light/dark cycle and free ac-
cess to standard food and tap water. The ani-
mals were kept and handled according to the 
local guidelines of care and work with labor-
atory animals in Isfahan University of Medi-
cal Sciences. 
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Chemicals 
Doxepin hydrochloride (Sigma, USA) 
and dexamethasone hydrochloride 
(Darupakhsh Company, Iran) were dissolved 
in isotonic saline. Formalin, glacial acetic 
acid and diethyl ether oxide (Merck, Darm-
stadt, Germany) were also used. 
Dibasic potassium phosphate (Merck, 
Germany), monobasic potassium phosphate 
(Merck, Germany), hexadecyl trimethyl am-
monium bromide (HTAB) and o-dianisidine 
dihydrochloride (o-dianisidine) (Sigma 
Chemical Co., St. Louis, Mo, USA), hydro-
gen peroxide (H2O2) was used for determina-
tion of myeloperoxidase (MPO) activity. 
TNF-α, IL-6 and IL-1β kits (Boster, USA) 
were used for measurement of the cytokines. 
Ketamine and xylazine vials (Alfasan, 
The Netherlands) were used for inducing an-
esthesia in rats.  
 
Surgical procedure  
To adapt the rats to manipulation and re-
duction their stress, they were handled for five 
days. Then a mixture of ketamine (40 mg/kg) 
and xylazine (7 mg/kg) by i.p. injection was 
used to anesthetize them. Then, the rats were 
fixed in a stereotaxic apparatus (Stoelting, 
USA), and according to Paxinos and Watson 
rat atlas, an i.c.v. cannula was implanted (AP: 
−0.8 mm; LR: 1.4 mm; UD: 3.3 mm) 
(Budantsev et al., 1992), the cannula was 
fixed by dental cement. 
A needle (no. 22) with 2 mm length was 
used as cannula and a needle (no. 30) was in-
serted inside the cannula for the drug injec-
tion. To check the right cannula implantation, 
the animals were sacrificed at the end and 
brain tissues were tested. 
 
Body weight measurement 
The rats were individually weighed by a 
digital balance (ACCU-LAB V-3000) at the 
start of the experiment and at the end of study 
in order to measure body weight changes.  
 
Induction of experimental colitis 
The animals were kept in stainless steel 
cages with a fasted and free access to water 
condition for about one day before colitis in-
duction. Acute colitis was induced by acetic 
acid as it was described previously 
(MacPherson and Pfeiffer, 1978). Diethyl 
ether as an anesthetic agent was inhaled to the 
rats placed in a desiccator. After the rats were 
lightly anesthetized, the whole of an 8 cm 
tube was inserted into the colon via the anus. 
Then acetic acid (3 ml, 3 % v/v in normal sa-
line) was entered into the colon slowly. Then 
for 30 sec they were held in a head down po-
sition to decrease leakage of the solution from 
anus. 
 
Experimental design 
The doses of doxepin were chosen from a 
pilot study. The following groups were de-
signed and the rats were distributed into each 
group randomly: 
Sham group (n=6): took normal saline 
(2 ml/kg, i.p.) without colitis induction; Con-
trol group (n=6): took normal saline (2 ml/kg, 
i.p.) 30 min prior to induction of colitis; Dex-
amethasone group (n=6): took dexame-
thasone (2 mg/kg, i.p.) 30 min prior to induc-
tion of colitis. Test groups (n=6): took dox-
epin (10, 20, 40 mg/kg twice a day, i.p. or 50, 
100 μg/rat/day, i.c.v.) 30 min prior to induc-
tion of colitis. 
Intracerebroventricular injections were 
accomplished slowly during 1 min through 
the cannula at the volume of 10 μl. 
Administration of medications was per-
formed for three successive days following of 
the colitis induction. All the drugs solutions 
were prepared freshly. 
 
Assessment of colon damage  
The animals were sacrificed in the fourth 
day of colitis induction by diethyl ether inha-
lation. The colons were separated and washed 
with normal saline quietly and weighed accu-
rately (Minaiyan et al., 2015). The 8 cm distal 
colons were assayed for macroscopic evalua-
tions and then the colons were fragmented 
into three pieces to use for histopathology as-
sessment, measuring MPO activity and cyto-
kine levels. The tissue segments for histo-
pathology assessment were kept in formalin 
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10 % and the segments for measuring MPO 
activity and cytokine levels were kept at 
freezer (-85 °C).  
 
Macroscopic assessment of colon injury 
The samples were photographed by digi-
tal camera (Sony, Japan) and the lesions were 
analyzed by a software (Fiji-win 32). Then an 
image processing and analysis software was 
done by NIH (National Institutes of Health) 
Image for the Macintosh (Ghosh et al., 2004). 
For assessment the severity of colitis macro-
scopically, five scores were chosen by an in-
dependent viewer. Summation of the follow-
ing grades were considered to calculate the 
macroscopic score: 
Number 0 for conditions without any 
macroscopic alterations, number 1 for only 
erythema conditions on colon’s mucosa tis-
sue, number 2 for mild conditions of edema or 
bleeding or erosion on mucosa tissue, number 
3 for moderate conditions of edema or ulcers 
or erosions, number 4 for severe conditions of 
edema or ulcers or erosions or necrosis 
(Deshmukh et al., 2010). Furthermore, ulcer 
area was measured for each specimen. Ulcer 
index was calculated using the following 
equation as described by Varshosaz et al. 
(2010). 
Ulcer index = Ulcer area (cm2) + Macro-
scopic score. 
 
Histopathological assessment of colon 
injury 
The colon pieces which had been fixed in 
formalin solution were dried and derived in 
paraffin and then cut into slices with 5 μm 
thickness. Then paraffin was cleaned by xy-
lene solution and the slices were dyed by HE 
method (hematoxylin and eosin staining pro-
tocol). Finally the dyed slices were scored as 
described previously (Rees, 1998) with some 
modifications. Total colitis index was meas-
ured by summing the scores of inflammation 
severity (0-3), inflammation extent (0-3), 
crypt damage (0-4) (Minaiyan et al., 2015). 
Assay for MPO activity 
Assessment of tissue MPO activity was 
carried out according to the technique de-
scribed by Bradley et al. (1982) with some 
modifications. Segments of the colon (0.1 g) 
were thawed in laboratory environment and 
crushed to prepare the suspensions. The sus-
pensions were homogenized in potassium 
phosphate buffer (50 mM, pH=6) plus HTAB 
(0.5 %) in an ice bath. It was applied enough 
buffer to make suspensions with 0.1 g tissue 
per 5 ml. Then the suspensions were respec-
tively sonicated (10 s, in an ice bath), worked 
under exposure of freezing-thawing cycle (3 
times), sonicated (10 s, in an ice bath) and 
centrifuged (15 min, 15000 rpm at 4 °C). Fi-
nally the supernatant of each suspension was 
extracted. The supernatants were added to 
phosphate buffer (50 mM, pH 6) containing 
O-dianisidine dihydrochloride (0.167 mg/ml) 
and hydrogen peroxide (0.0005 %) to make a 
solution with 0.1 ml (supernatant) to 2.9 ml 
(buffer) ratio. The absorbance of each final 
solution was recorded by a spectrophotometer 
(EPOCH, USA) at 460 nm. 
 
Determination of the cytokines levels in the 
colon tissue 
TNF-α, IL-6 and IL-1β levels in the colon 
tissues were evaluated by enzyme-linked im-
munosorbent assay (ELISA). Segments of the 
colon were thawed in laboratory environment 
and chopped to small pieces and were homo-
genized in 0.01 M PBS (pH=7.2-7.6) contain-
ing 8.5 g NaCl, 1.4 g Na2HPO4 and 0.2 g 
NaH2PO4 to 1000 ml distilled water. One ml 
PBS per 1 g tissue was used to prepare the su-
pernatant. The cytokines levels were meas-
ured according to kit instructions provided by 
the manufacturer (Boster Company). 
 
Statistical analysis 
Data are expressed as mean ± S.E.M 
which were analyzed by one-way ANOVA 
followed by Tukey’s post hoc test. Paired t-
test was applied for weigh changes compari-
son. All statistical analyses were made by us-
ing SPSS software (version 22).  
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RESULTS 
Animals' body weight changes 
Induction of experimental colitis caused 
loss of body weight during the experimental 
period in the control group. The rats were 
treated with doxepin (20, 40 mg/kg, i.p.) sig-
nificantly showed improvement in body 
weight loss at day 4. Dexamethasone 
(2 mg/kg, i.p.) as reference drug resulted in 
improvement of body weight loss too. In 
Sham group, three days experiment caused 
body weight gain as expected (P<0.001, 
paired t-test) (Table 1). 
 
Effect of doxepin on macroscopic  
parameters 
Resulting of colitis induction, the colons 
of control group displayed severe inflamma-
tion, ulceration, wall thickening, edema and 
sometimes necrosis, while colons of sham 
group showed intact epithelium with no dam-
age (Figure 1). One-way ANOVA followed 
by Tukey’s post hoc test revealed that weight 
of distal colon and ulcer index (summation of 
ulcer area and macroscopic score) were sig-
nificantly increased in control group during 
experimental period (P<0.01). Treatment 
with doxepin (20 and 40 mg/kg, i.p.) reduced 
both weight of colon and ulcer index com-
pared with control group (P<0.01) (Figures 2, 
3). With the dose of 10 mg/kg, doxepin re-
duced ulcer index and colon weight in less 
amount compared to its other doses (p<0.05). 
The effects of doxepin (20 and 40 mg/kg, i.p.) 
was nearly similar to dexamethasone 
(2 mg/kg, i.p.) (Figures 2, 3). 
 
 
Table 1: Effect of doxepin on body weight reduction before and after treatment. Data are presented as 
mean ± S.E.M (n=6). *P<0.05, **P<0.01, ***P<0.001, paired t-test. 
Weight (g) Sham Control 
Doxepin  
10 mg/kg, i.p. 
Doxepin  
20 mg/kg, i.p. 
Doxepin  
40 mg/kg, i.p. 
Dexamethasone 
2 mg/kg, i.p. 
Before  
treatment  222.4 225.6 201.1 210 223.5 216.2 
After  
treatment  240** 189*** 166.3** 190.3* 207* 193* 
Change % +7.91 -16.2 -17.3 -9.3 -7.3 -10.7 
 
 
 
Figure 1: Macroscopic presenta-
tion of rat colons in treatment 
groups. Sham: normal rats treated 
with normal saline which shows in-
tact colon, Control: control colitis 
treated with normal saline which 
shows the highest level of tissue 
injuries like edema, erythema, ul-
cer, necrosis and thickening of tis-
sue. Doxepin and dexamethasone 
treated colons represents healing 
of ulcers and obvious improve-
ment in tissue injuries. i.p.: intra-
peritoneal 
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Figure 2: Effect of doxepin (10, 20, 40 mg/kg, i.p.) 
and dexamethasone (Dex., 2 mg/kg, i.p.) on 
weight of 8 cm distal colon. Data are analysed as 
mean ± S.E.M, (n=6). *P<0.05, **P<0.01, 
***P<0.001 in comparison with control group, one-
way ANOVA followed by Tukey’s post hoc test. 
 
 
 
Figure 3: Effect of doxepin (10, 20, 40 mg/kg, i.p.) 
and dexamethasone (Dex., 2 mg/kg, i.p.) on ulcer 
index. Data are analysed as mean ± S.E.M, (n=6). 
*P<0.05, **P<0.01 in comparison with control 
group, one-way ANOVA followed by Tukey’s post 
hoc test. 
 
 
Doxepin (50 μg/rat and 100 μg/rat) after i.c.v. 
injection did not show any significant anti-co-
litis activity in rats in comparison with the 
control group (p<0.05) (Figures 4 and 5).  
 
 
Figure 4: Macroscopic presentation of rat colons 
in treatment groups. Sham: normal rats treated 
with normal saline which shows intact colon, Con-
trol: control colitis treated with normal saline which 
shows the high level of tissue injuries like edema, 
erythema, ulcer, necrosis and thickening of tissue. 
Doxepin: treated colitis with doxepin (50 and 
100 µg/rat. i.c.v.) which both of them show high 
level of tissue injuries like control colitis. i.c.v.: in-
tracerebroventricular injection. 
 
Figure 5: Effects of doxepin (50, 100 μg/rat, i.c.v.) 
on ulcer index. Results are presented as mean ± 
S.E.M, (n=6).  
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Effect of doxepin on histopathological  
features 
There was not any histological damage in 
sham group, so colonic mucosa had an intact 
epithelium. In contrast, control group showed 
edema, inflammation (existing of various in-
flammatory cells), trans-mural ulceration, cell 
infiltration into the mucosa and exfoliated and 
destroyed epithelium. Interestingly, goblet 
cells have been seen only in dexamethasone 
group unlike to doxepin groups (Figure 6). 
One-way ANOVA followed by Tukey’s 
post hoc test explained that total colitis index, 
including summation of inflammation sever-
ity, inflammation extent and crypt damage 
scores were significantly decreased in dox-
epin (20 and 40 mg/kg, i.p.) and dexame-
thasone (2 mg/kg, i.p.) groups in comparison 
with control groups (p<0.05), without any sig-
nificant improvement with doxepin at 10 mg/ 
kg, i.p. dose (Figure 7).  
 
 
Figure 7: Effect of doxepin (10, 20, 40 mg/kg, i.p.) 
and dexamethasone (Dex., 2 mg/kg, i.p.) on total 
colitis index. Data are analysed as mean ± S.E.M, 
(n=6). *P<0.05, **P<0.01 in comparison with con-
trol group, one-way ANOVA followed by Tukey’s 
post hoc test. 
 
 
 
Effect of doxepin on myeloperoxidase 
(MPO) activity 
One-way ANOVA followed by Tukey’s 
post hoc test revealed that MPO activity in co-
lonic tissue of the control group was signifi-
cantly increased (P<0.01) in comparison with 
sham group. Myeloperoxidase activity in co-
lonic tissues of dexamethasone group and all 
of doxepin groups (P<0.01) decreased in 
comparison with control group. Indeed, three 
increasing doses of doxepin had nearly the 
same effect on the level of MPO (Figure 8). 
 
 
 
Figure 6: Histopathological presentation of rat colons in treatment groups: (A) Appearance of a normal 
rat colon. (B) In control colitis group, great mucosal layer destruction with most inflammatory cell infil-
tration and cryptic damage are evident. (C) In dexamethasone group, the extent and severity of histo-
logical damage were attenuated while the goblet cells could be seen. (D, E, F) Improvements in histo-
pathology damage parameters were obvious especially with greater dose of doxepin (40 mg/kg). 
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Figure 8: Effect of doxepin (10, 20, 40 mg/kg, i.p.) 
and dexamethasone (Dex., 2 mg/kg, i.p.) on MPO 
activity of rat colon. Data are analysed as mean ± 
S.E.M, (n=6). *P<0.05, **P<0.01 in comparison 
with control group, one-way ANOVA followed by 
Tukey’s post hoc test. 
 
 
 
Effect of doxepin on the tissue cytokines 
One-way ANOVA with Tukey’s post hoc 
test showed that intracolonic instillation of 
acetic acid significantly (p<0.01) increased 
tissue levels of TNF-α, IL-6 and IL-1β in 
comparison with sham group (Figures 9-11). 
All three tested doses of doxepin (10, 20 
and 40 mg/kg twice daily, i.p.) and dexame-
thasone (2 mg/kg, i.p.) could decrease these 
cytokines (p<0.01) (Figures 9-11). However, 
there was no significant difference between 
20 and 40 mg/kg doses of doxepin for TNFα 
attenuation, two greater doses of 20 and 
40 mg/kg were more effective than the dose 
of 10 mg/kg in this respect (Figure 9). 
 
 
Figure 9: Effect of doxepin (10, 20, 40 mg/kg, i.p.) 
and dexamethasone (Dex., 2 mg/kg, i.p.) on TNF-
α. Data are analysed as mean ± S.E.M, (n=6). 
*P<0.05, **P<0.01, ***P<0.001 in comparison with 
control group, one-way ANOVA followed by 
Tukey’s post hoc test. 
 
Figure 10: Effect of doxepin (10, 20, 40 mg/kg, 
i.p.) and dexamethasone (Dex., 2 mg/kg, i.p.) on 
IL6. Data are analysed as mean ± S.E.M, (n=6). 
**P<0.01, ***P<0.001 in comparison with control 
group, one-way ANOVA followed by Tukey’s post 
hoc test. 
 
 
 
Figure 11: Effect of doxepin (10, 20, 40 mg/kg, 
i.p.) and dexamethasone (Dex., 2 mg/kg, i.p.) on 
IL1β. Data are presented as mean ± S.E.M, (n=6). 
**P<0.01, ***P<0.001 in comparison with control 
group, one-way ANOVA followed by Tukey’s post 
hoc test. 
 
DISCUSSION 
In previous studies it has figured out that 
antidepressants can inhibit inflammatory dis-
orders (Hajhashemi et al., 2010, 2015). In 
vitro studies have shown that some antide-
pressants reduce stimulated release of pro-in-
flammatory cytokines such as IL-1β, IL6, 
TNF-α and IFN-γ (Janssen et al., 2010). 
Sutcigil et al. (2007) found a decrease in ele-
vated TNF-α levels after selective serotonin 
reuptake inhibitors (SSRI). Sadeghi et al. 
(2011) showed that amitriptyline, as a TCA, 
reduced levels of IL-1β, TNF-α and MPO ac-
tivity into inflamed paw tissues. Interestingly, 
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Hinze-Selch et al. (2000) reported that ther-
apy with TCAs, but not SSRIs, activated the 
TNF-α system in patients. Hence, study on the 
effects of antidepressant drugs on the cyto-
kine levels and MPO activity is one of the ex-
perimental issues now. MPO activity acts as 
an indicator for oxidative stress magnitude in 
involved tissues. Decline in MPO activity af-
ter doxepin treatment suggests that antioxi-
dant capacities of colonic tissues are restored 
after treatment by different doses of doxepin 
(Sadeghi et al., 2011). 
There are some studies to explain the ben-
eficial outcome of antidepressant medications 
in IBD suffers. In a study, fluoxetine and 
desipramine showed anti-inflammatory effect 
in acetic-acid induced colitis in rats (Guemei 
et al., 2008). Anti-inflammatory effects of flu-
voxamine (Minaiyan et al., 2015), amitripty-
line (Fattahian et al., 2016) and maprotiline 
have investigated by Minaiyan et al. (2014) in 
acetic-acid induced colitis in rats. 
Doxepin as a TCA with some properties 
like H1, H2 and muscarinic receptor antago-
nistic activity was chosen as a suitable antide-
pressant for evaluation. 
To make a distinguish difference between 
its peripheral and central effects; the study 
was done by i.p. and i.c.v. administration of 
doxepin respectively. For this purpose, we ac-
complished a pilot study to determine an ap-
propriate dose range. Then the doses of 10, 20 
and 40 mg/kg twice daily for i.p. administra-
tion and 50 and 100 μg/rat for i.c.v. admin-
istration which were both effective and safe 
were chosen. 
The findings clearly explained that dox-
epin can inhibit colitis parameters in the vari-
ous applied i.p. doses and it has a potent anti-
inflammatory effect in acetic acid induced co-
litis in rat. It improved all of the colitic mark-
ers at applied doses. 
Intra-cerebraventricular (i.c.v.) admin-
istration of doxepin didn’t show any signifi-
cant effect on colitis. It means that peripheral 
mechanisms are necessary for doxepin action 
or activation in colitis improvement. It is no-
table that doxepin's active metabolite, 
desmethyldoxepin (nordoxepin), with antide-
pressant effect might be responsible at least 
for a part of doxepin effectiveness on colitis. 
Also doxepin by itself has some specific prop-
erties that can explain its peripheral effective-
ness on colitis. It binds strongly to the hista-
mine H1 and H2 receptors (Shibuya et al., 
2012; Ahles et al., 1984; Shimamura et al., 
2011) and has some antagonistic effects on 5-
HT, alpha1 adrenergic and muscarinic recep-
tors (Singh and Becker, 2007). The roles of 
these mediators in the pathogenesis of colitis 
have been previously investigated (Fogel et 
al., 2005; Ghia et al., 2009; Tolstanova et al., 
2010; Xie and He, 2005). 
We know that immune system dysregula-
tion has an important role in colitis pathogen-
esis, so it may be possible that doxepin can 
alter the immunity system by interacting with 
SNS main neurotransmitter, NE (Elenkov et 
al., 2000; Nance and Sanders, 2007). 
Some studies have indicated that trans-
porters of 5HT and NE are expressed on mon-
onuclear cells in peripheral blood circulation 
besides the CNS (Faraj et al., 1994; Fazzino 
et al., 2008; Urbina et al., 1999). Furthermore, 
immune cells such as lymphocytes and mon-
ocytes release serotonin and noradrenaline 
(Finocchiaro et al., 1998; Mossner and Lesch, 
1998). Thus, it is possible that the inhibitory 
effect of doxepin on the levels of cytokines in 
colitis tissues is resulted from its direct effects 
on the immune cells. 
Koh et al. (2011) showed that fluoxetine 
can directly inhibit NF-κβ signaling in intes-
tinal epithelial cells (IEC) and ameliorate ex-
perimental colitis. So inhibition of NF-κB sig-
naling could be one of the probable mecha-
nisms which doxepin decreases inflammatory 
mediators from the intestinal immune cells. 
Therefore assessment of NF-κB could be rec-
ommended in further experiments. 
Recent studies have declared the role of 
serotonin and its receptors in activation of im-
mune responses and inflammation (Shajib 
and Khan, 2015). Serotonin receptor (5HT3) 
inhibition by ondansetron (Motavallian-
Naeini et al., 2012), granisetron (Fakhfouri et 
al., 2010), tropisetron (Motavallian et al., 
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2013) or ramosetron (Min and Rhee, 2015) 
has beneficial property on experimental coli-
tis in rat. It has figured out that there are ser-
otoninergic receptors especially 5HT3 ones in 
immune system, so they have a significant 
role in infiltration and activation of macro-
phages into the inflamed intestine. Regarding 
to antagonistic effects of doxepin on 5HT1 re-
ceptors, its anti-colitis effects could be at-
tributed somewhat to its antihistaminic activ-
ity. 
Our findings are supportive for the studies 
investigating the role of antidepressants in 
management of depressed mood as well as 
visceral inflammation in IBD patients. Peri-
odic monitoring of IBD suffers for depressive 
disorders, is supportive to adjuvant therapy 
with an antidepressant. Also our findings re-
veal that doxepin could be a favorite candi-
date for relieve the comorbidities related to 
depression in patients with IBD, such as in-
somnia. Further studies are needed to intro-
duce doxepin as a safe and effective drug in 
prevention and/or treatment of IBD. 
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